Skip to Content

Phenylephrine Dosage

Medically reviewed by Drugs.com. Last updated on Jun 6, 2019.

Applies to the following strengths: 10 mg/mL; 2.5 mg; 10 mg; 1.25 mg/0.8 mL; 5 mg/5 mL; 50 mg/250 mL-NaCl 0.9%; 100 mcg/mL-NaCl 0.9%; 0.8 mg/10 mL-NaCl 0.9%; 40 mg/250 mL-NaCl 0.9%; 200 mcg/5 mL-NaCl 0.9%; 2.5 mg/5 mL; 80 mcg/mL-NaCl 0.9%; 20 mg/250 mL-NaCl 0.9%; 10 mg/250 mL-NaCl 0.9%; 10 mg/5 mL; 25 mg/250 mL-NaCl 0.9%; 30 mg/250 mL-NaCl 0.9%; 20 mg/50 mL-NaCl 0.9%; 40 mg/250 mL-D5%; 0.4 mg/10 mL-NaCl 0.9%; tannate 10 mg; tannate 7.5 mg/5 mL; 400 mcg/10 mL-NaCl 0.9%; 7.5 mg/5 mL; 100 mcg/mL

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Hypotension

Perioperative dosing (patients undergoing surgery with neuraxial or general anesthesia):
Initial dose: 50 to 250 mcg by intravenous bolus (most common doses: 50 to 100 mcg)
Maintenance dose: 0.5 to 1.4 mcg/kg/min by intravenous continuous infusion (titrate to blood pressure goal)

Septic or Other Vasodilatory Shock:
0.5 to 6 mcg/kg/min by intravenous continuous infusion (titrate to blood pressure goal)
-No bolus
-Doses over 6 mcg/kg/min do not show significant incremental blood pressure increases.

Usual Adult Dose for Shock

Perioperative dosing (patients undergoing surgery with neuraxial or general anesthesia):
Initial dose: 50 to 250 mcg by intravenous bolus (most common doses: 50 to 100 mcg)
Maintenance dose: 0.5 to 1.4 mcg/kg/min by intravenous continuous infusion (titrate to blood pressure goal)

Septic or Other Vasodilatory Shock:
0.5 to 6 mcg/kg/min by intravenous continuous infusion (titrate to blood pressure goal)
-No bolus
-Doses over 6 mcg/kg/min do not show significant incremental blood pressure increases.

Usual Adult Dose for Nasal Congestion

10 mg orally every 4 hours
Maximum dose: 60 mg per 24 hours

Usual Pediatric Dose for Nasal Congestion

12 years and older: 10 mg orally every 4 hours
Maximum dose: 60 mg per 24 hours

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Liver cirrhosis patients may have decreased response to this drug.
-Consider larger doses in hepatically impaired patients.

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to any of the ingredients
-Current use of a monoamine oxidase inhibitor (MAOI) or use within 14 days of stopping a MAOI.

Safety and efficacy of the oral formulations have not been established in patients younger than 12 years. Safety and efficacy of the intravenous formulations have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Hemodialysis: End stage renal disease (ESRD) on hemodialysis may have increased responsiveness to this drug; consider lower doses in these patients.
Peritoneal dialysis: Data not available

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions